Navigation Links
Alfacell Provides Shareholder Update
Date:6/19/2009

e drug resistance (MDR). A publication regarding this study is in the process of being completed.

To quote Zbigniew Darzynkiewicz, M.D., Ph.D. Professor of Pathology and Medicine; Director, Brander Cancer Research Institute, New York Medical College, a long time collaborator who has published numerous peer reviewed articles regarding the molecular mechanism of Onconase states the following: "We now have compelling evidence from numerous preclinical studies including investigations on animals that Onconase strongly enhances effect of many types of anticancer drugs. The enhancement of the anticancer effectiveness by Onconase was shown to involve prevention of the induction defense mechanism which generally are triggered by the anticancer drugs and provide resistance to treatment. This propensity of Onconase makes it an attractive candidate to be used as an adjunct to variety of cancer treatment protocols. In this capacity Onconase can be widely used in therapy of different tumor types, including most common types such as cancer of breast, prostate, colon, ovary and lung."

Another quote is provided by Harvey I. Pass. Director, New York University Medical Center, Division of Thoracic Surgery; Chief of Thoracic Oncology: "The promising subgroup analysis requested by the FDA exhibiting a significant survival advantage for those individuals previously treated with chemotherapy who received the combination of Onconase and doxorubicin points to molecular mechanisms of inherent or acquired chemotherapy resistance. It is known that there are specific chemotherapy resistance genes which not only are present in untreated mesotheliomas but also become over expressed when certain chemotherapeutic agents, including platinum, are used in the first line therapy of cancer. These genes, known as the multidrug resistance (MDR) gene1 and the multidrug resistance associated protein gene make proteins which act like pumps to keep ch
'/>"/>

SOURCE Alfacell Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Alfacell Provides ONCONASE(R) NDA Submission Update
2. Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacells ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines
3. Alfacell Announces ONCONASE(R) Distribution and Marketing Agreement with Megapharm for Israel
4. Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial
5. Alfacells ONCONASE(R) Shows Potential as Radiation Sensitizer for Lung Cancer Treatment
6. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
7. Alfacell Reports Financial Results for First Quarter of Fiscal 2008
8. Alfacell Corporation to Present at UBS Global Life Sciences Conference
9. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
10. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
11. Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... /PRNewswire/ - Anything Technologies Media, Inc. (OTC:EXMT) has announced ... Solutions (FIGS), www.frontiergarden.com has been announced ... Manager for a My Compassion originated medical cannabis ... in Alaska.  The project will be funded through ... Partners. The first phase of the project, is ...
(Date:7/30/2015)... July 30, 2015  Cardinal Health today reported ... an increase of 20 percent, and non-GAAP diluted ... $1.00, an increase of 20 percent. Non-GAAP operating ... a GAAP basis, operating earnings increased 44 percent ... operations increased 29 percent to $0.88. ...
(Date:7/30/2015)... 2015 ReportsnReports.com adds ... tumor biomarker tests, imaging, endoscopy and biopsy ... global industry by technology and application. ... Biomarker Tests, Imaging, Endoscopy and Biopsy) Report ... 9 companies and supported with 180 tables ...
Breaking Medicine Technology:Frontier Indoor Garden Solutions announced as Horticultural Supplier and Project Manager for Alaskan Tribal Medical Marijuana Grow Facility 2Frontier Indoor Garden Solutions announced as Horticultural Supplier and Project Manager for Alaskan Tribal Medical Marijuana Grow Facility 3Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 2Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 3Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 4Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 5Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 6Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 7Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 8Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 9Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 10Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 11Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 12Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 13Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 14Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 15Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 16Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 17Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 18Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 19Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 20Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 21Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 22Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 23Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 24Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 25Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 26Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 27Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 28Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 29Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 30Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 31Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 32Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 33Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 34
... Results,published this week in The Lancet show that ... 6, 11,16, 18) Recombinant Vaccine) was 100 percent ... by HPV,types 16 and 18, two types strongly ... observed in women who were not,infected with HPV ...
... at 9th International Symposium on,Myelodysplastic Syndromes, TAMPA, Fla., ... a pivotal Phase II trial evaluating Revlimid in ... syndromes (MDS),were presented today by Dr. Alan List, ... Institute, at the 9th International,Symposium on MDS currently ...
Cached Medicine Technology:Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 2Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 3Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 4Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 5Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 6Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 7Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 8Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 9Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 10Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 11Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 12Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 13Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 14Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 15Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 16Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 17Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 18Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 19Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 20Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 21Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 22Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 23Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 24Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 25Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 26Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 27Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 28Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 29Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 30Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 31Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 32Study Continues to Show Patients With Myelodysplastic Syndromes,Treated With Revlimid are Living Longer and Remaining Transfusion,Independent 2Study Continues to Show Patients With Myelodysplastic Syndromes,Treated With Revlimid are Living Longer and Remaining Transfusion,Independent 3
(Date:7/30/2015)... ... 2015 , ... Ross A. Clevens, MD, FACS has been reappointed ... Plastic Surgery. This is Dr. Clevens’ second appointment by the prestigious school. ... a strong presence and a valuable mentoring program for medical students. ...
(Date:7/30/2015)... ... 2015 , ... The Mesothelioma Applied Research Foundation (Meso Foundation) ... of 2015’. The bill was introduced in Congress yesterday by Representatives John Katko ... Joe Kennedy (D-MA), and Leonard Lance (R-NJ). The purpose of the bill is ...
(Date:7/30/2015)... Tampa, FL (PRWEB) , ... July 30, 2015 , ... ... to eradicate suicide and teach people more effective ways to prevent and manage major ... equipped to react fast enough, so people fall through the cracks and die needlessly ...
(Date:7/30/2015)... ... July 30, 2015 , ... Boston ... the annual All-Stars Summit. Google Partners is the platform for search marketing agencies ... full support and tools necessary to run successful search marketing campaigns. Google Partners ...
(Date:7/30/2015)... ... 2015 , ... Between 2012 and 2014 HIV infection rates rose from five ... June 17th. Those untreated heroin use disorders share their needles and spread the infection. ... throughout the community. Ultimately Florida’s HIV infection rates have bolstered to 23 percent due ...
Breaking Medicine News(10 mins):Health News:Leading Melbourne Facial Plastic Surgeon Reappointed by UCF 2Health News:Leading Melbourne Facial Plastic Surgeon Reappointed by UCF 3Health News:Bill to Create Patient Registry for Deadly Cancer Introduced in Congress 2Health News:Happiness Expert Develops Pioneering Online Tools for Sufferers of Major Depression, and Who may be Suicidal 2Health News:Happiness Expert Develops Pioneering Online Tools for Sufferers of Major Depression, and Who may be Suicidal 3Health News:Boston Web Marketing Attends Google Partners All-Stars Summit 2Health News:HIV Rates Rise in S. Florida, Harbor Village Comments on Health News Florida's Recent Article 2Health News:HIV Rates Rise in S. Florida, Harbor Village Comments on Health News Florida's Recent Article 3
... Institute of Environmental Health Sciences (NIEHS), conducted a study ... starch predisposes to respiratory problems. // ,"These ... Stephanie London, M.D., lead investigator on the study. "We ... data from such a large number of participants to ...
... in US and in San Francisco. Asian spas offering Ayurveda, ... in San Francisco. Many of them have included Asian methods, ... spent $11.2 billion in going to spas in 2003. According ... in the year - nearly one visit for every two ...
... flu panic fallowing reports of a pigeon dead. The ... and identification of the virus responsible for the pigeon ... of the virulent H5N1 strain of bird flu in ... not spread from other countries through migratory birds, as ...
... be the new Director of Edinburgh University, which will ... UK Government. The Government of United Kingdom has funded ... avenues in the treatment of Leukemia, Hodgkin’s lymphoma, diabetes, ... unspecialized blood cell that has the capacity to replicate ...
... the University of Alberta has revealed that different parts of ... performing the same tasks. This goes to prove that the ... differently. The volunteers for the study were called upon to ... memory tasks, while the functional Magnetic Resonance Imaging (fMRI) technology ...
... mothers who are about to deliver premature babies, as the ... survival rates are lower // . Annie Janvier and Keith ... the records of about 72 babies who ran the risk ... and came to the conclusion that the conversations that the ...
Cached Medicine News:Health News:Ayurveda Spas are hot in San Francisco 2
... SPRING-GRIP™ single use nonconductive anchoring devices are ... mm and 12 mm sizes for use ... mm, 5 mm-10 mm, 5 mm-11 mm, ... sizes for use with the VERSAPORT™, SURGISPIKE™, ...
... line of Surgical Access ...unlike any trocar ... trocar system is actually four systems in ... flexible and clinically adaptive to all of ... disposability and bladed or dilating tip styles, ...
... FPK01 Thoracic Trocar Pak contains: ... flexible sleeves and (1) 12mm ... ,FPK02 Thoracic Trocar Pak contains: ... flexible sleeves., ,FPK03 Thoracic ...
... of three separate components: an exchange rod, a ... transparent trocar sleeve. The exchange rod is a ... long. The dilating obturator is tapered and threaded ... opening created by the 10/11mm or the 12mm ...
Medicine Products: